Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC

Cancer Research

Volumn 58, Issue 14, 1998, Pages 3094-3100

  Schoenberger, Stephen P ^a,c   Jonges, Liesbeth E ^a   Mooijaart, Rob J D ^a   Hartgers, Franca ^a   Toes, Rene E M ^a   Kast, W Martin ^b   Melief, Cornelius J M ^a   Offringa, Rienk ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; GENETIC ENGINEERING; HELPER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION;

EID: 0032527927     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I., and Hellstrom, K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med., 179: 523-532, 1994.
2. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med., 177: 1791-1796, 1993.
3. + T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
4. Huang, A. Y., Golumbeck, P., Ahmadzadeh, M., Jaffe, E., Pardoll, D. M., and Levitsky, H. I. Role of bone marrow-derived cells in presenting MHC class Irestricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
5. Huang, A. Y. C., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. Does B7.1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med., 183: 769-776, 1996.
6. Chambers, B. J., Salcedo, M., and Ljunggren, H-G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity, 5: 311-317, 1996.
7. Wu, T-C., Huang, A. Y. C., Jaffee, E. M., Levitsky, H. I., and Pardoll, D. M. A reassessment of the role of B7.1 expression in tumor rejection. J. Exp. Med., 182: 1415-1421, 1995.
8. Yeh, K-Y., Pulaski, B. A., Woods, M. L., McAdam, A. J., Gaspari, A. A., Frelinger, J. G., and Lord, E. M. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol., 165: 217-224, 1995.
9. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tornaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G. Co-expression of B7.1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol., 25: 1154-1162, 1995.
10. Geldhof, A. B., Raes, G., Bakkus, M., Devos, S., Thielmans, K., and De Bastelier, P. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res., 55: 2730-2733, 1995.
11. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., Van der Eb, A. J., and Melief, C. J. M. Eradication of adenovirus E1-induced tumors by E1a-specific cytotoxic T lymphocytes. Cell, 59: 603-614, 1989.
12. Toes, R. E. M., Blom, R. J. J., van der Voort, E., Offringa, R., Melief, C. J. M., and Kast, W. M. Protective anti-tumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res., 56: 3782-3787, 1996.
13. Toes, R. E. M., Blom, R. J. J., Offringa, R., Kast, W. M., and Melief, C. J. M. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumorspecific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol., 156: 3911-3918, 1996.
14. Toes, R. E. M., van der Voort, E. I. H., Schoenberger, S. P., Drijfhout, J. W., Bloois, L., Storm, G., Kast, W. M., Offringa, R., and Melief, C. J. M. Enhancement of tumor-outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells, J. Immunol., 160: 4446-4449, 1998.
15. Toes, R. E. M., Offringa, R., Blom, R. J. J., Brandt, R. M. P., Van der Eb, A. J., Melief, C. J. M., and Kast, W. M. An adenovirus type 5 early region 1B-encoded CTL-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol., 154: 3396-3405, 1995.
16. Sanderson, S., and Shastri, N. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol., 6: 369-376, 1994.
17. th American Peptide Symposium, p. 1003. Leiden: ESCOM, 1990.
18. Sarmiento, M., Glasebrook, A. L., and Fitch, F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol., 125: 2665-2672, 1980.
19. Dialynas, D. P., Quan, Z. S., Wall, K. A., Pierres, A., Quintans, J., Loken, M. R., Pierres, M., and Fitch, F. W. Characterization of the murine T cell surface molecule, designated L3T4, identified by the monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol., 131: 2445-2451, 1983.
20. Koo, G. C., Dumont, F. J., Tutt, M., Hackett, J., and Kumar, V. The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J. Immunol., 137: 3742-3747, 1986.
21. Anderson, K., Cresswell, P., Gammon, M., Hermes. J., Williamson, A., and Zweerink, H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J, Exp. Med., 174: 489-492, 1991.
22. Kundig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J. L., Battegay, M., Lother, H., Gessner, A., Kuhlcke, K., Ohashi, P. S., Hengartner, H., and Zinkernagel, R. M. Fibroblasts as efficient antigen-presenting cells in lymphoid organs, Science (Washington DC), 268: 1343-1347, 1995.
23. Townsend, S. E., Su, F. W., Atherton, J. M., and Allison, J. P. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors, Cancer Res., 54: 6477-6483, 1994.
24. Huang, A. Y. C., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. In vivo cross priming of MHC class I-restricted antigens requires the TAP transporter. Immunity, 4: 339-355, 1996.
25. Neisig, A., Roelse, J., Sijts, A. J. A. M., Ossendorp, F., Feltkamp, M. C. W., Kast, W. M., Melief, C. J. M., and Neefjes, J. J. Major differences in transporter associated with antigen processing (TAP)-dependent translocation of MHC class I-presentable peptides and effect of flanking sequences. J. Immunol., 154: 1273-1279, 1995.
26. Armstrong, T. D., Clements, V. K., and Ostrand-Rosenberg, S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J. Immunol., 160: 661-666, 1998.
27. Cayeux, S., Richter, G., Noffz, G., Dorken, B., and Blankenstein, T. Influence of gene-modified (II-7, IL-4, and B7.1) tumor cell vaccines on tumor antigen presentation. J. Immunol., 158: 2834-2841, 1997.
28. Sercarz, E. E., Lehmann, P. V., Ametani, A., Benichou, G., Miller, A., and Mougdil, K. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol., 11: 729-766, 1993.